Evaluation of the feasibility and efficacy of point-of-care antibody tests for biomarker guided management of COVID-19.
Cavan S ReillyEleftherios MylonakisRobin DewarBarnaby YoungJacqueline NordwallSanjay BhaganiPo-Ying ChiaRuby DavisClark FilesAdit A GindeTimothy J HatlenMarie HellebergAwori HayangaTomas O JensenMamta K JainIoannis KalomenidisKami KimPerrine LallemandBirgitte LindegaardAnupama MenonKatherine OgnenovskaGaryfallia PoulakouBirgit Thorup RøgeAngela J RogersKaty Shaw-SalibaUriel SandkovskyBarbara W TrautnerShikha S VasudevaAndrew VeksteinKimberley ViensJames WyncollBrian DuChateauZhenxing ZhangShujiang WuAbdel G BabikerVictoria J DaveyAnnetine GelijnsElizabeth HiggsVirginia KanJens Dilling LundgrenGail V MatthewsH Cliff LanePublished in: The Journal of infectious diseases (2024)
Although both POC tests deviated moderately from the GenScript assay, they predicted outcomes of interest. The RightSign test was easier to use and was more likely to detect those lacking antibody compared to the LumiraDX test treating GenScript as the gold standard.